Prognostic significance of the expression of HER family members in primary osteosarcoma

Wang,Sheng‑Lin; Zhong,Guang‑Xian; Wang,Xin‑Wen; Yu,Feng‑Qiang; Weng,Dan‑Feng; Wang,Xin‑Xing; Lin,Jian‑Hua

doi:10.3892/ol.2018.8931

Prognostic significance of the expression of HER family members in primary osteosarcoma

Authors:
- Sheng‑Lin Wang
- Guang‑Xian Zhong
- Xin‑Wen Wang
- Feng‑Qiang Yu
- Dan‑Feng Weng
- Xin‑Xing Wang
- Jian‑Hua Lin
View Affiliations

Affiliations: Department of Orthopedics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China, Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China
Published online on: June 8, 2018 https://doi.org/10.3892/ol.2018.8931
Pages: 2185-2194
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis of patients with metastatic osteosarcoma is poor and has shown no significant improvement in nearly 20 years. The human epidermal growth factor (EGF) receptor (HER) family is frequently overexpressed in the majority of human carcinomas, and is involved in promoting the proliferation and survival of cancer cells. However, the role of EGFR and HER‑2 expression in osteosarcoma survival remains controversial and no previous study has simultaneously investigated the association of the expression of all the four HER family members with the prognostic significance of osteosarcoma. Therefore, the present study investigated the expression levels of the complete members of the HER family in osteosarcoma specimens, as well as their associations with the clinicopathological parameters, progression‑free survival (PFS) and overall survival (OS) time of patients with osteosarcoma. The expression of HER family members was detected in osteosarcoma tumor specimens from 60 patients using immunohistochemistry. The association of the expression of HER receptors in osteosarcoma with clinicopathological parameters was analyzed using χ2 test and Fishers exact test. Survival analyses were evaluated by Kaplan‑Meier method and Cox proportional hazards regression model. Overall, 18 (30%), 13 (22%), 23 (38%) and 19 (32%) patients presented with high expression of EGFR, HER‑2, HER‑3 and HER‑4, respectively, and the co‑expression of 2, 3 and all 4 members of the HER family was observed. High expression of EGFR and HER‑4 was associated with distant metastasis. High HER‑3 expression was significantly associated with an advanced Enneking stage and distant metastasis. Multivariate analysis demonstrated that the expression of EGFR, HER‑3, HER‑4, EGFR/HER‑3, EGFR/HER‑4 and HER‑3/HER‑4 was an independent predictor of poor PFS and OS time in osteosarcoma patients with stage I‑IIB disease. In patients with stage IIB osteosarcoma, the expression of HER‑4 and EGFR/HER‑4 demonstrated a more significant effect on PFS and OS time. In conclusion, therapies targeting EGFR, HER‑3 and HER‑4 may provide promising strategies for primary osteosarcoma.

View Figures

View References

1	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
2	Zhou W, Hao M, Du X, Chen K, Wang G and Yang J: Advances in targeted therapy for osteosarcoma. Discov Med. 17:301–307. 2014.PubMed/NCBI
3	De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A and Normanno N: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 214:559–567. 2008. View Article : Google Scholar : PubMed/NCBI
4	Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol. 33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
5	Renoir JM, Marsaud V and Lazennec G: Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol. 85:449–465. 2013. View Article : Google Scholar : PubMed/NCBI
6	Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, Casey O, Chen WY, Fang L, Hynes P, et al: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget. 5:3770–3784. 2014. View Article : Google Scholar : PubMed/NCBI
7	Xu L, Wu H, Jiang C, Wang H, Gao B, Yan S, Qi Y and Zhou S: Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells. Discov Med. 22:297–309. 2016.PubMed/NCBI
8	Do SI, Jung WW, Kim HS and Park YK: The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int J Oncol. 34:797–803. 2009.PubMed/NCBI
9	Lee JA, Ko Y, Kim DH, Lim JS, Kong CB, Cho WH, Jeon DG, Lee SY and Koh JS: Epidermal growth factor receptor: Is it a feasible target for the treatment of osteosarcoma? Cancer Res Treat. 44:202–209. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kersting C, Gebert C, Agelopoulos K, Schmidt H, van Diest PJ, Juergens H, Winkelmann W, Kevric M, Gosheger G, Brandt B, et al: Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clin Cancer Res. 13:2998–3005. 2007. View Article : Google Scholar : PubMed/NCBI
11	Baxevanis CN, Sotiropoulou PA, Sotiriadou NN and Papamichail M: Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother. 53:166–175. 2004. View Article : Google Scholar : PubMed/NCBI
12	Abdou AG, Kandil M, Asaad NY, Dawoud MM, Shahin AA and Eldayem Abd AF: The prognostic role of Ezrin and HER2/neu expression in osteosarcoma. Appl Immunohistochem Mol Morphol: AIMM. 24:355–363. 2016. View Article : Google Scholar
13	Yalcin B, Gedikoğlu G, Kutluk T, Varan A, Akyüz C and Büyükpamukçu M: C-erbB-2 expression and prognostic significance in osteosarcoma. Pediatric Blood Cancer. 51:222–227. 2008. View Article : Google Scholar : PubMed/NCBI
14	Zhang Q, Liu F, Wang B, Li Z, Zhou D, Yang Q, Dong J and Li J: HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies. Medicine. 95:e36612016. View Article : Google Scholar : PubMed/NCBI
15	Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, Yamashita T, Sawada N, Yamawaki S and Ishii S: ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer. 94:1397–1404. 2002. View Article : Google Scholar : PubMed/NCBI
16	Geller DS and Gorlick R: HER-2 targeted treatment of osteosarcoma: The challenges of developing targeted therapy and prognostic factors for rare malignancies. Exp Opin Pharmacother. 11:51–61. 2010. View Article : Google Scholar
17	Ma J, Lyu H, Huang J and Liu B: Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer. 13:1052014. View Article : Google Scholar : PubMed/NCBI
18	Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R and Geller DS: Cell surface receptor expression patterns in osteosarcoma. Cancer. 118:740–749. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hughes DP, Thomas DG, Giordano TJ, Baker LH and McDonagh KT: Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 64:2047–2053. 2004. View Article : Google Scholar : PubMed/NCBI
20	Hua Y, Yang Y and Hughes D: Abstract 197: Multi-cellular tumor spheroids in vitro model reveals a critical role of ERBB4 in survival of osteosarcoma. Cancer Res. 71:197. 2011. View Article : Google Scholar : PubMed/NCBI
21	Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 106–120. 1980.PubMed/NCBI
22	Srirajaskanthan R, Shah T, Watkins J, Marelli L, Khan K and Caplin ME: Expression of the HER-1–4 family of receptor tyrosine kinases in neuroendocrine tumours. Oncol Rep. 23:909–915. 2010. View Article : Google Scholar : PubMed/NCBI
23	Liu Q, Hao L, Lou Z, Gao X, Gong H, Hong Y, Fu C and Zhang W: Survival time and prognostic factors of patients with initial noncurative colorectal liver metastases. Medicine (Baltimore). 96:e88312017. View Article : Google Scholar : PubMed/NCBI
24	Wu H, Sharp GC, Zhao Q, Shirato H and Jiang SB: Statistical analysis and correlation discovery of tumor respiratory motion. Phys Med Biol. 52:4761–4774. 2007. View Article : Google Scholar : PubMed/NCBI
25	Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T and Osaki Y: Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett. 6:1213–1218. 2013. View Article : Google Scholar : PubMed/NCBI
26	Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, Gelderblom H, Hogendoorn PC, Egeler RM, Schilham MW and Lankester AC: Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res. 18:432–441. 2012. View Article : Google Scholar : PubMed/NCBI
27	Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX and Harari PM: Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res. 73:824–833. 2013. View Article : Google Scholar : PubMed/NCBI
28	Huang Z, Wang Y, Nayak PS, Dammann CE and Sanchez-Esteban J: Stretch-induced fetal type II cell differentiation is mediated via ErbB1-ErbB4 interactions. J Biol Chem. 287:18091–18102. 2012. View Article : Google Scholar : PubMed/NCBI
29	Silva SD, Alaoui-Jamali MA, Hier M, Soares FA, Graner E and Kowalski LP: Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread. Clin Exp Metastasis. 31:307–316. 2014. View Article : Google Scholar : PubMed/NCBI
30	Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M, Egeler RM and Hogendoorn PC: Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer. 40:963–970. 2004. View Article : Google Scholar : PubMed/NCBI
31	Maitra A, Wanzer D, Weinberg AG and Ashfaq R: Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer. 92:677–683. 2001. View Article : Google Scholar : PubMed/NCBI
32	Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH and Bos GD: Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol. 14:1277–1283. 2001. View Article : Google Scholar : PubMed/NCBI
33	Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, Bacci G, Zanella L, Bertoni F, Picci P and Serra M: Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. 41:1349–1361. 2005. View Article : Google Scholar : PubMed/NCBI
34	Yoshida R, Tazawa H, Hashimoto Y, Yano S, Onishi T, Sasaki T, Shirakawa Y, Kishimoto H, Uno F, Nishizaki M, et al: Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. Cancer Immunol Immunother. 61:1905–1916. 2012. View Article : Google Scholar : PubMed/NCBI
35	Long XH, Zhang GM, Peng AF, Luo QF, Zhang L, Wen HC, Zhou RP, Gao S, Zhou Y and Liu ZL: Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro. Oncol Rep. 31:328–334. 2014. View Article : Google Scholar : PubMed/NCBI
36	Jullien N, Maudinet A, Leloutre B, Ringe J, Häupl T and Marie PJ: Downregulation of ErbB3 by Wnt3a contributes to wnt-induced osteoblast differentiation in mesenchymal cells. J Cell Biochem. 113:2047–2056. 2012. View Article : Google Scholar : PubMed/NCBI
37	Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 220:24–33. 2010. View Article : Google Scholar : PubMed/NCBI
38	Xu H, Liu X and Zhao J: Down-regulation of miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem. 33:1547–1556. 2014. View Article : Google Scholar : PubMed/NCBI
39	Bianchi S, Palli D, Falchetti M, Saieva C, Masala G, Mancini B, Lupi R, Noviello C, Omerovic J, Paglierani M, et al: ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study. J Cell Physiol. 206:702–708. 2006. View Article : Google Scholar : PubMed/NCBI
40	Karamouzis MV, Badra FA and Papavassiliou AG: Breast cancer: The upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol. 39:851–856. 2007. View Article : Google Scholar : PubMed/NCBI
41	Citri A and Yarden Y: EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006. View Article : Google Scholar : PubMed/NCBI
42	Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, et al: Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 14:648–655. 2015. View Article : Google Scholar : PubMed/NCBI